Dear Reader,
Have you ever wondered how much a small cap stock can move after receiving FDA approval?
It's staggering.
These companies can experience a surge that sends them into new dimensions. One example of this phenomenon is Kala Pharmaceuticals.
Kala Pharmaceuticals' stock took off after receiving FDA approval, soaring to new heights.
Reata Pharmaceuticals is another company that saw a huge price surge.
After obtaining the FDA's approval in February, its stock price tripled overnight.
And these are just two of endless examples of what the head nod from the administration can do for a stock.
That's why we are over the moon about this newly listed NASDAQ company, Mainz Biomed (NASDAQ:MYNZ) and its game-changing cancer (CRC) screening technology.
This company's revolutionary product is moving at breakneck speed toward FDA approval after completing a successful Pre-Submission Process in March 2022.
Mainz Biomed's (NASDAQ:MYNZ) ColoAlert is a non-invasive genetic-based screening test for colorectal cancer. This product is extremely accurate and user-friendly.
ColoAlert is already approved and currently marketed in the EU, it should be available in the US in the not-so-distant future once the FDA approves it.
By 2027, the cancer screening market is projected to double in value and reach $281.4 billion and if Mainz Biomed continues on this upward trajectory, it could be a key player in this billion dollar market.
Why New Colorectal Cancer Screening Methods Like Mainz Biomed's Are Desperately Needed
ColoAlert also stands out in the market because it's backed by a business model that is more convenient and cost-efficient compared to what other companies are doing.
ColoAlert takes advantage of third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. The company expects to use this same model in the US, differentiating it from the competition, all of which follow a centralized model.
In other words, ColoAlert and Mainz Biomed (NASDAQ:MYNZ) are potential market game-changers in not one but two different ways, and the company has its sights set firmly on surpassing the current market leader – Exact Sciences' ColoGuard.
Once ColoGuard was approved by the FDA in 2014, Exact Sciences was off to the races, growing from a $400 million market cap up to its current value of nearly $12 billion.
Not to mention Exact brought in screening revenue of over $1.5 billion in 2022,yet it's only addressing 8% of the potential US market so far, leaving plenty of room for Mainz Biomed to capture market share.
All of that is why we believe Mainz Biomed (NASDAQ:MYNZ) and its revolutionary product ColoAlert deserves a closer look.
Tell me everything I need to know about Mainz Biomed (NASDAQ:MYNZ) now
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
The above is a paid advertisement. Barchart.com is not affiliated with nor does it endorse any trading system, newsletter or other similar service. Barchart.com does not guarantee or verify any performance claims made by such systems, newsletters or services. Trading involves a significant and substantial risk of loss and may not be suitable for everyone. You should only trade with money you can afford to lose. There is no guarantee that you will profit from your trading activity and it is possible that you may lose all of, or if trading on margin more than, your investment. Some of the results shown may be based on simulated performance. SIMULATED OR HYPOTHETICAL PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE THE RESULTS SHOWN IN AN ACTUAL PERFORMANCE RECORD, SUCH RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, BECAUSE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MY HAVE UNDER OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED OR HYPOTHETICAL PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN. Past performance is not necessarily indicative of future performance. This brief statement cannot disclose all the risks and other significant aspects of trading. You should carefully study trading and consider whether such activity is suitable for you in light of your circumstances and financial resources before you trade.
This message is considered by regulation to be a commercial and advertising message. This is a permission-based message. You are receiving this email either because you opted-in to this subscription or because you have a prior existing relationship with Barchart.com or one of its subsidiaries, and previously provided your email address to us. This email fully complies with all laws and regulations. If you do not wish to receive this email, then we apologize for the inconvenience. You can immediately discontinue receiving this email by clicking on the unsubscribe or profile link and you will no longer receive this email. We will immediately redress any complaints you may have. If you have any questions, please send an email with your questions to bcmembers@barchart.com.
Barchart.com
209 W. Jackson Blvd., 2nd Floor, Chicago, IL 60606
Unsubscribe
No comments:
Post a Comment